IL-17 for therapy

Journal of Dermatological Science

Volumn 87, Issue 3, 2017, Pages 221-227

  Kurschus, Florian C ^a   Moos, Sonja ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Autoimmunity; IL 17; IL 17 neutralizing monoclonal antibodies; IL 17 receptor; Psoriasis

Indexed keywords

ADALIMUMAB; ADAMTS LIKE PROTEIN 5; ADAMTS PROTEIN; BRODALUMAB; COSYNTEX; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23; IXEKIZUMAB; SECUKINUMAB; TALZ; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IL17A PROTEIN, HUMAN; IL17A PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SIGNAL TRANSDUCTION; SUICIDAL IDEATION; SUICIDE ATTEMPT; ANIMAL; ANKYLOSING SPONDYLITIS; ANTAGONISTS AND INHIBITORS; DERMATITIS; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PROCEDURES; SKIN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATITIS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION; SKIN; SPONDYLITIS, ANKYLOSING;

EID: 85020518169     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2017.06.010     Document Type: Review

References (102)

1. Rouvier, E., Luciani, M.F., Mattei, M.G., Denizot, F., Golstein, P., CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150:12 (1993), 5445–5456.
2. Yao, Z., Fanslow, W.C., Seldin, M.F., Rousseau, A.M., Painter, S.L., Comeau, M.R., Cohen, J.I., Spriggs, M.K., Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:6 (1995), 811–821.
3. Gaffen, S.L., Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23:5 (2011), 613–619.
4. Hymowitz, S.G., Filvaroff, E.H., Yin, J.P., Lee, J., Cai, L., Risser, P., Maruoka, M., Mao, W., Foster, J., Kelley, R.F., Pan, G., Gurney, A.L., de Vos, A.M., Starovasnik, M.A., IL-17 s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 20:19 (2001), 5332–5341.
5. Ely, L.K., Fischer, S., Garcia, K.C., Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10:12 (2009), 1245–1251.
6. Yao, Z., Painter, S.L., Fanslow, W.C., Ulrich, D., Macduff, B.M., Spriggs, M.K., Armitage, R.J., Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155:12 (1995), 5483–5486.
7. Lockhart, E., Green, A.M., Flynn, J.L., IL-17 production is dominated by gammadelta T cells rather than CD4T cells during Mycobacterium tuberculosis infection. J. Immunol. 177:7 (2006), 4662–4669.
8. Takatori, H., Kanno, Y., Watford, W.T., Tato, C.M., Weiss, G., Ivanov II, Littman, D.R., O'Shea, J.J., Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206:1 (2009), 35–41.
9. Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J.P., Eberl, G., Koyasu, S., Locksley, R.M., McKenzie, A.N., Mebius, R.E., Powrie, F., Vivier, E., Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13:2 (2013), 145–149.
10. Rachitskaya, A.V., Hansen, A.M., Horai, R., Li, Z., Villasmil, R., Luger, D., Nussenblatt, R.B., Caspi, R.R., Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 180:8 (2008), 5167–5171.
11. Hueber, A.J., Asquith, D.L., Miller, A.M., Reilly, J., Kerr, S., Leipe, J., Melendez, A.J., McInnes, I.B., Mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol. 184:7 (2010), 3336–3340.
12. Taylor, P.R., Roy, S., Leal, S.M. Jr., Sun, Y., Howell, S.J., Cobb, B.A., Li, X., Pearlman, E., Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORgammat and dectin-2. Nat. Immunol. 15:2 (2014), 143–151.
13. Chang, S.H., Dong, C., A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 17:5 (2007), 435–440.
14. Wright, J.F., Guo, Y., Quazi, A., Luxenberg, D.P., Bennett, F., Ross, J.F., Qiu, Y., Whitters, M.J., Tomkinson, K.N., Dunussi-Joannopoulos, K., Carreno, B.M., Collins, M., Wolfman, N.M., Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J. Biol. Chem. 282:18 (2007), 13447–13455.
15. Liang, S.C., Long, A.J., Bennett, F., Whitters, M.J., Karim, R., Collins, M., Goldman, S.J., Dunussi-Joannopoulos, K., Williams, C.M., Wright, J.F., Fouser, L.A., An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 179:11 (2007), 7791–7799.
16. Hu, Y., Ota, N., Peng, I., Refino, C.J., Danilenko, D.M., Caplazi, P., Ouyang, W., IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 184:8 (2010), 4307–4316.
17. Toy, D., Kugler, D., Wolfson, M., Vanden Bos, T., Gurgel, J., Derry, J., Tocker, J., Peschon, J., Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177:1 (2006), 36–39.
18. Ho, A.W., Shen, F., Conti, H.R., Patel, N., Childs, E.E., Peterson, A.C., Hernandez-Santos, N., Kolls, J.K., Kane, L.P., Ouyang, W., Gaffen, S.L., IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 185:2 (2010), 1063–1070.
19. Kuestner, R.E., Taft, D.W., Haran, A., Brandt, C.S., Brender, T., Lum, K., Harder, B., Okada, S., Ostrander, C.D., Kreindler, J.L., Aujla, S.J., Reardon, B., Moore, M., Shea, P., Schreckhise, R., Bukowski, T.R., Presnell, S., Guerra-Lewis, P., Parrish-Novak, J., Ellsworth, J.L., Jaspers, S., Lewis, K.E., Appleby, M., Kolls, J.K., Rixon, M., West, J.W., Gao, Z., Levin, S.D., Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J. Immunol. 179:8 (2007), 5462–5473.
20. Haudenschild, D., Moseley, T., Rose, L., Reddi, A.H., Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J. Biol. Chem. 277:6 (2002), 4309–4316.
21. Nagata, T., McKinley, L., Peschon, J.J., Alcorn, J.F., Aujla, S.J., Kolls, J.K., Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells. J. Immunol. 181:11 (2008), 7473–7479.
22. Ishigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., Tanahashi, Y., Akitsu, A., Kotaki, H., Sudo, K., Nakae, S., Sasakawa, C., Iwakura, Y., Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30:1 (2009), 108–119.
23. Olsson Akefeldt, S., Maisse, C., Belot, A., Mazzorana, M., Salvatore, G., Bissay, N., Jurdic, P., Arico, M., Rabourdin-Combe, C., Henter, J.I., Delprat, C., Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A. PLoS One, 8(2), 2013, e56865.
24. Chang, S.H., Park, H., Dong, C., Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281:47 (2006), 35603–35607.
25. Awane, M., Andres, P.G., Li, D.J., Reinecker, H.C., NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J. Immunol. 162:9 (1999), 5337–5344.
26. Zepp, J., Wu, L., Li, X., IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 32:5 (2011), 232–239.
27. Wu, L., Chen, X., Zhao, J., Martin, B., Zepp, J.A., Ko, J.S., Gu, C., Cai, G., Ouyang, W., Sen, G., Stark, G.R., Su, B., Vines, C.M., Tournier, C., Hamilton, T.A., Vidimos, A., Gastman, B., Liu, C., Li, X., A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. J. Exp. Med. 212:10 (2015), 1571–1587.
28. Sebkova, L., Pellicano, A., Monteleone, G., Grazioli, B., Guarnieri, G., Imeneo, M., Pallone, F., Luzza, F., Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect. Immun. 72:9 (2004), 5019–5026.
29. Gaffen, S.L., Jain, R., Garg, A.V., Cua, D.J., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14:9 (2014), 585–600.
30. Iyoda, M., Shibata, T., Kawaguchi, M., Hizawa, N., Yamaoka, T., Kokubu, F., Akizawa, T., IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am. J. Physiol. Renal Physiol. 298:3 (2010), F779–F787.
31. Li, J.K., Nie, L., Zhao, Y.P., Zhang, Y.Q., Wang, X., Wang, S.S., Liu, Y., Zhao, H., Cheng, L., IL-17 mediates inflammatory reactions via p38/c-Fos and JNK/c-Jun activation in an AP-1-dependent manner in human nucleus pulposus cells. J. Transl. Med., 14, 2016, 77.
32. Rumzhum, N.N., Patel, B.S., Prabhala, P., Gelissen, I.C., Oliver, B.G., Ammit, A.J., IL-17A increases TNF-alpha-induced COX-2 protein stability and augments PGE2 secretion from airway smooth muscle cells: impact on beta2-adrenergic receptor desensitization. Allergy 71:3 (2016), 387–396.
33. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J.J., Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., Rouvier, E., Golstein, P., Banchereau, J., Lebecque, S., T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:6 (1996), 2593–2603.
34. Chang, S.H., Dong, C., Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell. Signal. 23:7 (2011), 1069–1075.
35. Ruddy, M.J., Wong, G.C., Liu, X.K., Yamamoto, H., Kasayama, S., Kirkwood, K.L., Gaffen, S.L., Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J. Biol. Chem. 279:4 (2004), 2559–2567.
36. Liang, S.C., Tan, X.Y., Luxenberg, D.P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., Fouser, L.A., Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:10 (2006), 2271–2279.
37. Sonnenberg, G.F., Nair, M.G., Kirn, T.J., Zaph, C., Fouser, L.A., Artis, D., Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207:6 (2010), 1293–1305.
38. Hartupee, J., Liu, C., Novotny, M., Li, X., Hamilton, T., IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179:6 (2007), 4135–4141.
39. Johnston, A., Guzman, A.M., Swindell, W.R., Wang, F., Kang, S., Gudjonsson, J.E., Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br. J. Dermatol. 171:1 (2014), 97–107.
40. Cho, J.S., Pietras, E.M., Garcia, N.C., Ramos, R.I., Farzam, D.M., Monroe, H.R., Magorien, J.E., Blauvelt, A., Kolls, J.K., Cheung, A.L., Cheng, G., Modlin, R.L., Miller, L.S., IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120:5 (2010), 1762–1773.
41. Ye, P., Rodriguez, F.H., Kanaly, S., Stocking, K.L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., Shellito, J.E., Bagby, G.J., Nelson, S., Charrier, K., Peschon, J.J., Kolls, J.K., Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194:4 (2001), 519–527.
42. Saijo, S., Ikeda, S., Yamabe, K., Kakuta, S., Ishigame, H., Akitsu, A., Fujikado, N., Kusaka, T., Kubo, S., Chung, S.H., Komatsu, R., Miura, N., Adachi, Y., Ohno, N., Shibuya, K., Yamamoto, N., Kawakami, K., Yamasaki, S., Saito, T., Akira, S., Iwakura, Y., Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 32:5 (2010), 681–691.
43. Monin, L., Griffiths, K.L., Slight, S., Lin, Y., Rangel-Moreno, J., Khader, S.A., Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge. Mucosal. Immunol. 8:5 (2015), 1099–1109.
44. Conti, H.R., Bruno, V.M., Childs, E.E., Daugherty, S., Hunter, J.P., Mengesha, B.G., Saevig, D.L., Hendricks, M.R., Coleman, B.M., Brane, L., Solis, N., Cruz, J.A., Verma, A.H., Garg, A.V., Hise, A.G., Richardson, J.P., Naglik, J.R., Filler, S.G., Kolls, J.K., Sinha, S., Gaffen, S.L., IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis. Cell Host Microbe 20:5 (2016), 606–617.
45. Levy, R., Okada, S., Beziat, V., Moriya, K., Liu, C., Chai, L.Y., Migaud, M., Hauck, F., Al Ali, A., Cyrus, C., Vatte, C., Patiroglu, T., Unal, E., Ferneiny, M., Hyakuna, N., Nepesov, S., Oleastro, M., Ikinciogullari, A., Dogu, F., Asano, T., Ohara, O., Yun, L., Della Mina, E., Bronnimann, D., Itan, Y., Gothe, F., Bustamante, J., Boisson-Dupuis, S., Tahuil, N., Aytekin, C., Salhi, A., Al Muhsen, S., Kobayashi, M., Toubiana, J., Abel, L., Li, X., Camcioglu, Y., Celmeli, F., Klein, C., AlKhater, S.A., Casanova, J.L., Puel, A., Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc. Natl. Acad. Sci. U. S. A. 113:51 (2016), E8277–E8285.
46. Okada, S., Puel, A., Casanova, J.L., Kobayashi, M., Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin. Transl. Immunol., 5(12), 2016, e114.
47. Ling, Y., Cypowyj, S., Aytekin, C., Galicchio, M., Camcioglu, Y., Nepesov, S., Ikinciogullari, A., Dogu, F., Belkadi, A., Levy, R., Migaud, M., Boisson, B., Bolze, A., Itan, Y., Goudin, N., Cottineau, J., Picard, C., Abel, L., Bustamante, J., Casanova, J.L., Puel, A., Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212:5 (2015), 619–631.
48. Saunte, D.M., Mrowietz, U., Puig, L., Zachariae, C., Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br. J. Dermatol, 2016, 10.1111/bjd.15015.
49. Mathur, A.N., Chang, H.C., Zisoulis, D.G., Stritesky, G.L., Yu, Q., O'Malley, J.T., Kapur, R., Levy, D.E., Kansas, G.S., Kaplan, M.H., Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178:8 (2007), 4901–4907.
50. Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., Metin, A., Karasuyama, H., Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448:7157 (2007), 1058–1062.
51. Holland, S.M., DeLeo, F.R., Elloumi, H.Z., Hsu, A.P., Uzel, G., Brodsky, N., Freeman, A.F., Demidowich, A., Davis, J., Turner, M.L., Anderson, V.L., Darnell, D.N., Welch, P.A., Kuhns, D.B., Frucht, D.M., Malech, H.L., Gallin, J.I., Kobayashi, S.D., Whitney, A.R., Voyich, J.M., Musser, J.M., Woellner, C., Schaffer, A.A., Puck, J.M., Grimbacher, B., STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:16 (2007), 1608–1619.
52. Milner, J.D., Brenchley, J.M., Laurence, A., Freeman, A.F., Hill, B.J., Elias, K.M., Kanno, Y., Spalding, C., Elloumi, H.Z., Paulson, M.L., Davis, J., Hsu, A., Asher, A.I., O'Shea, J., Holland, S.M., Paul, W.E., Douek, D.C., Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:7188 (2008), 773–776.
53. Song, X., Qian, Y., IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell. Signal. 25:12 (2013), 2335–2347.
54. Choi, G.B., Yim, Y.S., Wong, H., Kim, S., Kim, H., Kim, S.V., Hoeffer, C.A., Littman, D.R., Huh, J.R., The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science 351:6276 (2016), 933–939.
55. Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M.H., G. Psoriasis Study, Durez, P., Tak, P.P., Gomez-Reino, J.J., G. Rheumatoid Arthritis Study, Foster, C.S., Kim, R.Y., Samson, C.M., Falk, N.S., Chu, D.S., Callanan, D., Nguyen, Q.D., G. Uveitis Study, Rose, K., Haider, A., Di Padova, F., Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med., 2(52), 2010 52ra72.
56. Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., Papavassilis, C., Group, E.S., Group, F.S., Secukinumab in plaque psoriasis–results of two phase 3 trials. N. Engl. J. Med. 371:4 (2014), 326–338.
57. McInnes, I.B., Sieper, J., Braun, J., Emery, P., vanderHeijde, D., Isaacs, J.D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., Ma, S., Schumacher, M.M., Bertolino, A.P., Hueber, W., Tak, P.P., Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73:2 (2014), 349–356.
58. Gisondi, P., Dalle Vedove, C., Girolomoni, G., Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol. Ther. 4:1 (2014), 1–9.
59. Baeten, D., Baraliakos, X., Braun, J., Sieper, J., Emery, P., van der Heijde, D., McInnes, I., van Laar, J.M., Landewe, R., Wordsworth, P., Wollenhaupt, J., Kellner, H., Paramarta, J., Wei, J., Brachat, A., Bek, S., Laurent, D., Li, Y., Wang, Y.A., Bertolino, A.P., Gsteiger, S., Wright, A.M., Hueber, W., Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:9906 (2013), 1705–1713.
60. Burkett, P.R., Kuchroo, V.K., IL-17 blockade in psoriasis. Cell, 167(7), 2016, 1669.
61. Nash, P., McInnes, I.B., Mease, P.J., Choy, E.H., Thom, H., Kalyvas, C., Gandhi, K., Mpofu, S., Jugl, S., Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparison. Arthritis Rheumatol., 68(Suppl. 10), 2016.
62. Thaci, D., Blauvelt, A., Reich, K., Tsai, T.F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., Milutinovic, M., Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol. 73:3 (2015), 400–409.
63. Gordon, K.B., Blauvelt, A., Papp, K.A., Langley, R.G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S.G., Braun, D.K., Cameron, G.S., Erickson, J., Konrad, R.J., Muram, T.M., Nickoloff, B.J., Osuntokun, O.O., Secrest, R.J., Zhao, F., Mallbris, L., Leonardi, C.L., Group, U.-S., U.-S. Group, U.-S. Group, Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 375:4 (2016), 345–356.
64. Song, X., Zhu, S., Shi, P., Liu, Y., Shi, Y., Levin, S.D., Qian, Y., IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12:12 (2011), 1151–1158.
65. Rickel, E.A., Siegel, L.A., Yoon, B.R., Rottman, J.B., Kugler, D.G., Swart, D.A., Anders, P.M., Tocker, J.E., Comeau, M.R., Budelsky, A.L., Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 181:6 (2008), 4299–4310.
66. Johnston, A., Fritz, Y., Dawes, S.M., Diaconu, D., Al-Attar, P.M., Guzman, A.M., Chen, C.S., Fu, W., Gudjonsson, J.E., McCormick, T.S., Ward, N.L., Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190:5 (2013), 2252–2262.
67. Papp, K.A., Leonardi, C., Menter, A., Ortonne, J.P., Krueger, J.G., Kricorian, G., Aras, G., Li, J., Russell, C.B., Thompson, E.H., Baumgartner, S., Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:13 (2012), 1181–1189.
68. Danesh, M.J., Kimball, A.B., Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J. Am. Acad. Dermatol. 74:1 (2016), 190–192.
69. Chiricozzi, A., Romanelli, M., Saraceno, R., Torres, T., No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin. Drug Saf. 15:12 (2016), 1653–1659.
70. Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P.D., Wehkamp, J., Feagan, B.G., Yao, M.D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A.P., Tougas, G., Travis, S.P., G. Secukinumab in Crohn's Disease Study, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:12 (2012), 1693–1700.
71. Kunwar, S., Dahal, K., Sharma, S., Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol. Int. 36:8 (2016), 1065–1075.
72. Kugyelka, R., Kohl, Z., Olasz, K., Mikecz, K., Rauch, T.A., Glant, T.T., Boldizsar, F., Enigma of IL-17 and Th17Cells in rheumatoid arthritis and in autoimmune animal models of arthritis. Mediators Inflamm., 2016, 2016, 6145810.
73. Havrdova, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., Garren, H., Maguire, R.P., Johns, D.R., Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J. Neurol. 263:7 (2016), 1287–1295.
74. Papp, K.A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J.G., Lacour, J.P., Menter, A., Philipp, S., Sofen, H., Tyring, S., Berner, B.R., Visvanathan, S., Pamulapati, C., Bennett, N., Flack, M., Scholl, P., Padula, S.J., Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N. Engl. J. Med. 376:16 (2017), 1551–1560.
75. Kulig, P., Musiol, S., Freiberger, S.N., Schreiner, B., Gyulveszi, G., Russo, G., Pantelyushin, S., Kishihara, K., Alessandrini, F., Kundig, T., Sallusto, F., Hofbauer, G.F., Haak, S., Becher, B., IL-12 protects from psoriasiform skin inflammation. Nat. Commun., 7, 2016, 13466.
76. Patel, D.D., Kuchroo, V.K., Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity 43:6 (2015), 1040–1051.
77. Torres, T., Romanelli, M., Chiricozzi, A., A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin. Investig. Drugs 25:7 (2016), 751–754.
78. Bartlett, H.S., Million, R.P., Targeting the IL-17-T(H)17 pathway. Nat. Rev. Drug Discov. 14:1 (2015), 11–12.
79. Isono, F., Fujita-Sato, S., Ito, S., Inhibiting RORgammat/Th17 axis for autoimmune disorders. Drug Discov. Today 19:8 (2014), 1205–1211.
80. Bronner, S.M., Zbieg, J.R., Crawford, J.J., RORgamma antagonists and inverse agonists: a patent review. Expert Opin. Ther. Patents 27:1 (2017), 101–112.
81. van der Fits, L., Mourits, S., Voerman, J.S., Kant, M., Boon, L., Laman, J.D., Cornelissen, F., Mus, A.M., Florencia, E., Prens, E.P., Lubberts, E., Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182:9 (2009), 5836–5845.
82. Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thurlimann, W., Burg, G., Nestle, F.O., Dummer, R., Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140:12 (2004), 1490–1495.
83. Ramirez-Valle, F., Gray, E.E., Cyster, J.G., Inflammation induces dermal Vgamma4+ gammadeltaT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc. Natl. Acad. Sci. U. S. A. 112:26 (2015), 8046–8051.
84. Pantelyushin, S., Haak, S., Ingold, B., Kulig, P., Heppner, F.L., Navarini, A.A., Becher, B., Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122:6 (2012), 2252–2256.
85. Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V.R., Zhang, H.G., Wang, T., Zheng, J., Yan, J., Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35:4 (2011), 596–610.
86. El Malki, K., Karbach, S.H., Huppert, J., Zayoud, M., Reissig, S., Schuler, R., Nikolaev, A., Karram, K., Munzel, T., Kuhlmann, C.R., Luhmann, H.J., von Stebut, E., Wortge, S., Kurschus, F.C., Waisman, A., An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Dermatol. 133:2 (2013), 441–451.
87. Mabuchi, T., Takekoshi, T., Hwang, S.T., Epidermal CCR6+ {gamma}{delta} T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J. Immunol. 187:10 (2011), 5026–5031.
88. Laggner, U., Di Meglio, P., Perera, G.K., Hundhausen, C., Lacy, K.E., Ali, N., Smith, C.H., Hayday, A.C., Nickoloff, B.J., Nestle, F.O., Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2T cell subset with a potential role in psoriasis. J. Immunol. 187:5 (2011), 2783–2793.
89. Perera, G.K., Di Meglio, P., Nestle, F.O., Psoriasis. Annu. Rev. Pathol. 7 (2012), 385–422.
90. Besgen, P., Trommler, P., Vollmer, S., Prinz, J.C., Ezrin, maspin, peroxiredoxin 2, and heat shock protein 27: potential targets of a streptococcal-induced autoimmune response in psoriasis. J. Immunol. 184:9 (2010), 5392–5402.
91. Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G., Feldmeyer, L., Marinari, B., Chon, S., Vence, L., Riccieri, V., Guillaume, P., Navarini, A.A., Romero, P., Costanzo, A., Piccolella, E., Gilliet, M., Frasca, L., The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun., 5, 2014, 5621.
92. Arakawa, A., Siewert, K., Stohr, J., Besgen, P., Kim, S.M., Ruhl, G., Nickel, J., Vollmer, S., Thomas, P., Krebs, S., Pinkert, S., Spannagl, M., Held, K., Kammerbauer, C., Besch, R., Dornmair, K., Prinz, J.C., Melanocyte antigen triggers autoimmunity in human psoriasis. J. Exp. Med. 212:13 (2015), 2203–2212.
93. Ortega, C., Fernandez, A.S., Carrillo, J.M., Romero, P., Molina, I.J., Moreno, J.C., Santamaria, M., IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 86:2 (2009), 435–443.
94. Di Meglio, P., Villanova, F., Navarini, A.A., Mylonas, A., Tosi, I., Nestle, F.O., Conrad, C., Targeting CD8(+) T cells prevents psoriasis development. J. Allergy Clin. Immunol. 138:1 (2016), 274–276 e6.
95. Cheuk, S., Wiken, M., Blomqvist, L., Nylen, S., Talme, T., Stahle, M., Eidsmo, L., Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol. 192:7 (2014), 3111–3120.
96. Takahashi, H., Numasaki, M., Lotze, M.T., Sasaki, H., Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 98:2 (2005), 189–193.
97. Walter, A., Schafer, M., Cecconi, V., Matter, C., Urosevic-Maiwald, M., Belloni, B., Schonewolf, N., Dummer, R., Bloch, W., Werner, S., Beer, H.D., Knuth, A., van den Broek, M., Aldara activates TLR7-independent immune defence. Nat. Commun., 4, 2013, 1560.
98. Haak, S., Croxford, A.L., Kreymborg, K., Heppner, F.L., Pouly, S., Becher, B., Waisman, A., IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119:1 (2009), 61–69.
99. Hafner, M., Wenk, J., Nenci, A., Pasparakis, M., Scharffetter-Kochanek, K., Smyth, N., Peters, T., Kess, D., Holtkotter, O., Shephard, P., Kudlow, J.E., Smola, H., Haase, I., Schippers, A., Krieg, T., Muller, W., Keratin 14 Cre transgenic mice authenticate keratin 14 as an oocyte-expressed protein. Genesis 38:4 (2004), 176–181.
100. Croxford, A.L., Karbach, S., Kurschus, F.C., Wortge, S., Nikolaev, A., Yogev, N., Klebow, S., Schuler, R., Reissig, S., Piotrowski, C., Brylla, E., Bechmann, I., Scheller, J., Rose-John, S., Wunderlich, F.T., Munzel, T., von Stebut, E., Waisman, A., IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. J. Invest. Dermatol. 134:3 (2014), 728–735.
101. Karbach, S., Croxford, A.L., Oelze, M., Schuler, R., Minwegen, D., Wegner, J., Koukes, L., Yogev, N., Nikolaev, A., Reissig, S., Ullmann, A., Knorr, M., Waldner, M., Neurath, M.F., Li, H., Wu, Z., Brochhausen, C., Scheller, J., Rose-John, S., Piotrowski, C., Bechmann, I., Radsak, M., Wild, P., Daiber, A., von Stebut, E., Wenzel, P., Waisman, A., Munzel, T., Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler. Thromb. Vasc. Biol. 34:12 (2014), 2658–2668.
102. Uluckan, O., Jimenez, M., Karbach, S., Jeschke, A., Grana, O., Keller, J., Busse, B., Croxford, A.L., Finzel, S., Koenders, M., van den Berg, W., Schinke, T., Amling, M., Waisman, A., Schett, G., Wagner, E.F., Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci. Transl. Med., 8(330), 2016 330ra37.